Skip to main content
OpenTrials
Completed

NCT Number: NCT02271334

Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers

The objective of this study is to evaluate the pharmacokinetics (PK) and safety profiles of A006, an Albuterol dry powder inhaler (DPI), following a single dose of 110 mcg (T1) or 220 mcg (T2), in healthy male and female adult volunteers.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Amphastar Site 0035

Cypress, California, 90630, United States

About this study

This study is a randomized, double or evaluator-blinded, single dose, four-arm, crossover PK study in eighteen (18) healthy volunteers, both male and female adults, at 18-40 years of age.

All candidates will be screened and only those who satisfy all enrollment criteria will be enrolled into this study. Each study subject will participate in a screening visit and four (4) study visits with one (1) randomized study treatment given in each visit.

PK samples will be analyzed with an established LC/MS/MS method. An End-of-Study (EOS) safety evaluation will be conducted at the end of Study Visit-4.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Generally healthy, male and female adults, 18-40 years of age at Screening;
  • Having no clinically significant respiratory, cardiovascular and other systemic or organic illnesses;
  • Body weight ≥ 50 kg for men and ≥ 45 kg for women, and BMI within the range of 18.5 - 30.0 kg/m2 inclusive;
  • Sitting blood pressure ≤ 135/90 mmHg;
  • Demonstrating negative HIV, HBsAg and HCV tests, alcohol and nine panel urine drug screen tests;
  • Demonstrating proficiency in the use of DPI and MDI or able to be trained in the proper use of these devices;
  • Demonstrating Peak Inspiratory Flow Rate (PIF) within 80-150 L/min (after training), for at least 2 times consecutively, with a maximum of 5 attempts;
  • Having no known hypersensitivity to any ingredients of A006 and Proventil® MDI (Albuterol, sulfate, lactose, milk protein, HFA-134a, oleic acid, or ethanol). (Subjects must be able to tolerate at least one teaspoon of milk);
  • Women of child-bearing potential must be non-pregnant, non-lactating, and practicing a clinically acceptable form of birth control; and
  • Having properly consented and satisfied all other inclusion/exclusion criteria as required for this protocol.

Exclusion criteria

  • A smoking history of ≥ 5 pack-years, or having smoked within 6 months prior to Screening;
  • Upper respiratory tract infections within 2 weeks, or lower respiratory tract infection within 4 weeks, prior to Screening;
  • Previous history of asthma or COPD;
  • Any current or recent respiratory conditions that, per investigator discretion, might significantly affect pharmacodynamic response to the study drugs, including cystic fibrosis, bronchiectasis, tuberculosis, emphysema, and other significant respiratory diseases;
  • Concurrent clinically significant cardiovascular, hematological, renal, neurologic, hepatic, endocrine, psychiatric, malignant, or other illnesses that in the opinion of the investigator could impact on the conduct, safety and evaluation of the study;
  • ECG at Screening and Visit-1 baseline expressed any single or multiple premature ventricular contractions (PVC);
  • ECG at Screening and Visit-1 baseline with a QTc reading greater than 450ms;
  • Use of prohibited drugs or failure to observe the drug washout restrictions; and
  • Having been on other clinical drug/device studies or donated blood in the last 30 days prior to Screening.

Treatment and study plan

A006 DPI

Drug

Single dose 110 mcg, 1 inhalation

Other names: Albuterol, Albuterol DPI

Proventil® MDI

Drug

Single dose 90 mcg, 1 inhalation

Other names: Proventil®

Primary outcomes

  1. Area Under the Curve of Drug Concentration versus Time (AUC[0-t])

    Time frame: Within 30 minutes prior to dosing (baseline) to 8 hours post-dose

    Subject PK blood samples will be taken prior to dosing and at multiple time points, up to 8 hours after dosing during each treatment period. PK samples will be analyzed using a validated test method. Area under the curve of the drug concentration versus time curve (AUC[0-t]) for each treatment period will be calculated using the trapezoidal rule.

  2. Peak Plasma Concentration (C[max])

    Time frame: Within 30 minutes prior to dosing (baseline) to 8 hours post-dose

    Subject PK blood samples will be taken prior to dosing and at multiple time points, up to 8 hours after dosing during each treatment period. PK samples will be analyzed using a validated test method. Peak plasma concentration (C[max]) will be the highest concentration of Albuterol during each treatment period.

  3. Time to Reach Peak Plasma Concentration (t[max])

    Time frame: Within 30 minutes prior to dosing (baseline) to 8 hours post-dose

    Subject PK blood samples will be taken prior to dosing and at multiple time points, up to 8 hours after dosing during each treatment period. PK samples will be analyzed using a validated test method. Time to reach peak plasma concentration (t[max]) will be the time it takes to reach the highest concentration of Albuterol during each treatment period.

  4. Plasma Albuterol Concentrations at All Time Points

    Time frame: Within 30 minutes prior to dosing (baseline) to 8 hours post-dose

    Subject PK blood samples will be taken prior to dosing and at multiple time points, up to 8 hours after dosing during each treatment period. PK samples will be analyzed using a validated test method. Plasma Albuterol concentrations at these time points will be reported during each treatment period.

Other outcomes

  1. Systolic Blood Pressure (SBP) at Screening

    Time frame: Within 14 days prior to Day 1 (Visit 1)

    Subjects will have their vital signs, i.e., blood pressure and heart rate, measured during the Screening Visit to ensure they are generally healthy.

  2. Systolic Blood Pressure (SBP)

    Time frame: Within 30 minutes prior to dosing (baseline) to 8 hours post-dose

    Subject will have their vital signs, i.e., blood pressure and heart rate, measured prior to dosing and at multiple time points, up to 8 hours after dosing during each treatment period.

  3. Diastolic Blood Pressure (DBP) at Screening

    Time frame: Within 14 days prior to Day 1 (Visit 1)

    Subjects will have their vital signs, i.e., blood pressure and heart rate, measured during the Screening Visit to ensure they are generally healthy.

  4. Diastolic Blood Pressure (DBP)

    Time frame: Within 30 minutes prior to dosing (baseline) to 8 hours post-dose

    Subject will have their vital signs, i.e., blood pressure and heart rate, measured prior to dosing and at multiple time points, up to 8 hours after dosing during each treatment period.

  5. Heart Rate (HR) at Screening

    Time frame: Within 14 days prior to Day 1 (Visit 1)

    Subjects will have their vital signs, i.e., blood pressure and heart rate, measured during the Screening Visit to ensure they are generally healthy.

  6. Heart Rate (HR)

    Time frame: Within 30 minutes prior to dosing (baseline) to 8 hours post-dose

    Subject will have their vital signs, i.e., blood pressure and heart rate, measured prior to dosing and at multiple time points, up to 8 hours after dosing during each treatment period.

  7. 12-Lead ECG QT Intervals at Screening

    Time frame: Within 14 days prior to Day 1 (Visit 1)

    12-Lead ECGs will be performed to measure QT and QTc intervals during the Screening Visit to ensure absence of overt cardiac illnesses.

  8. 12-Lead ECG QT Intervals

    Time frame: Within 30 minutes prior to dosing (baseline) to 8 hours post-dose

    12-Lead ECGs will be performed to measure QT and QTc intervals prior to dosing and at multiple time points, up to 8 hours after dosing during each treatment period.

  9. 12-Lead ECG QTc Intervals at Screening

    Time frame: Within 14 days prior to Day 1 (Visit 1)

    12-Lead ECGs will be performed to measure QT and QTc intervals during the Screening Visit to ensure absence of overt cardiac illnesses.

  10. 12-Lead ECG QTc Intervals

    Time frame: Within 30 minutes prior to dosing (baseline) to 8 hours post-dose

    12-Lead ECGs will be performed to measure QT and QTc intervals prior to dosing and at multiple time points, up to 8 hours after dosing during each treatment period.

  11. Complete Blood Count (CBC) at Screening

    Time frame: Within 14 days prior to Day 1 (Visit 1)

    A CBC will be performed as part of the subject safety evaluations at screening.

  12. Complete Blood Count (CBC) at End-of-Study

    Time frame: 4 hours post-dose at Visit 4 (within 6 weeks after Day 1 (Visit 1))

    A CBC will be performed as part of the End-of-Study subject safety evaluations at end-of-study.

  13. Comprehensive Metabolic Panel (CMP) at Screening

    Time frame: Within 14 days prior to Day 1 (Visit 1)

    A CMP will be performed as part of the subject safety evaluations at screening.

  14. Comprehensive Metabolic Panel (CMP) at End-of-Study

    Time frame: 4 hours post-dose at Visit 4 (within 6 weeks after Day 1 (Visit 1))

    A CMP will be performed as part of the End-of-Study subject safety evaluations at end-of-study.

  15. Urinalysis at Screening

    Time frame: Within 14 days prior to Day 1 (Visit 1)

    Routine and microscopic urinalysis will be performed as part of the subject safety evaluations at screening.

  16. Urinalysis at End-of-Study

    Time frame: 4 hours post-dose at Visit 4 (within 6 weeks after Day 1 (Visit 1))

    Routine and microscopic urinalysis will be performed as part of the End-of-Study subject safety evaluations at end-of-study.

  17. Incidents of Pregnancy at Screening

    Time frame: Within 14 days prior to Day 1 (Visit 1)

    A urinary pregnancy test will be performed for women of child-bearing potential as a part of the Screening Visit evaluations to determine the eligibility of the subject for the study.

  18. Incidents of Pregnancy at End-of-Study

    Time frame: 4 hours post-dose at Visit 4 (within 6 weeks after Day 1 (Visit 1))

    A urinary pregnancy test will be performed for women of child-bearing potential as a part of the End-of-Study safety evaluations to determine if a pregnancy had occurred during the study.

  19. Serious Adverse Events

    Time frame: Signing of Informed Consent at Screening Visit to End-of-Study Visit, an expected average of 7 Weeks

    Adverse drug events (ADEs), whether observed by investigators or reported by the subjects, will be documented, evaluated, followed up, and treated if deemed necessary. According to FDA guidelines, a serious ADE will refer to any adverse drug experience occurring at any dose that results in any of the following outcomes: 1) death; 2) a life-threatening adverse drug experience; 3) inpatient hospitalization or prolongation of existing hospitalization; 4) persistent or significant disability/incapacity; 5) congenital anomaly/birth defect; 6) other important medical events that may jeopardize the subject or may require medical or surgical intervention to prevent one of the outcomes listed in this definition. ADEs will be followed until stabilized/resolved or 30 days from the date the subject has finished the study, whichever is sooner.

  20. Other Adverse Events

    Time frame: Signing of Informed Consent at Screening Visit to End-of-Study Visit, an expected average of 7 Weeks

    Adverse drug events (ADEs), whether observed by investigators or reported by the subjects, will be documented, evaluated, followed up, and treated if deemed necessary. ADEs will be followed until stabilized/resolved or 30 days from the date the subject has finished the study, whichever is sooner.

Sponsors and collaborators

Lead sponsor

Amphastar Pharmaceuticals, Inc.

Industry

Registry information

Official study title

Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers (A Randomized, Double- or Evaluator-blinded, Single-dose, Four-arm, Crossover Pharmacokinetics (PK) Study in Healthy Adults)

Acronym: A006-D

Important dates

Study start
2014
Primary completion
2014
Study completion
2015
First posted
Oct 22, 2014
Registry last updated
Apr 19, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.